XNCR · Xencor Inc
$25.33
+0.56 (+2.26%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.77B
Shares
74.35M
Volume · Oct 2
48.26K
Avg daily vol (3M)
1.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.77
Open$24.57
Day$24.38–25.28
52W close$10.41–29.30
Avg vol 30d1.5M
Short int15.8M · 21.2% float · 13.2d
Short vol52%
Last earningsMay 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Dec 29, 2026
Est · unconfirmed
· in 13 wks
filed Aug 5, 2026
call held Feb 27, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$104.97M
Trailing 12 months
Net income (TTM)
−$163.11M
Trailing 12 months
Revenue growth YoY
+17.5%
Year over year
Operating margin
-205.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-11.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+109.4%
Trailing year
Short interest
21.2%
Latest settlement · 13.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+56%
above
Price vs 50-day avg
+3%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
76%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+99%
trailing
YTD return
+62%
this year
Relative strength
+87%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $24 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.18% of float · ▲ +5.6% MoM · 13.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
208 holders — near 3-yr high, broad support
Squeeze score
86
high risk · 0–100
Fundamentals
Revenue growth
+14%
Y/Y
EPS growth
+65%
Y/Y
Free cash flow
$-138.3M
Balance sheet
$65.7M
net debt
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Cash, cash equivalents and marketable debt securities
· year end 2026
$420M – $440M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+56%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
76%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $24 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.18% of float · ▲ +5.6% MoM · 13.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
208 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10
Now $25 · 76%
Range high $29
vs 200-day avg +56%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XNCR
this stock
Xencor Inc
|
$1.77B | +61.8% | +13.7% | — | 21.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XNCR | +3.7% | -7.9% | +99.4% | -0.7% | +61.8% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +4.2% | -7.8% | +87.0% | -0.9% | +49.8% |